TURKISH JOURNAL OF HEMATOLOGY, vol.34, no.1, pp.72-80, 2017 (SCI-Expanded)
Objective: This paper prospectively evaluates the long-term follow-up [mean +/- standard deviation (SD) duration: 89.7 +/- 19.4 months] data of 15 patients (13 females and 2 males) with refractory symptomatic immune thrombocytopenia (ITP) treated with rituximab.